- Research Article
- 10.1016/j.arth.2025.10.075
2025 ICM: Abbreviated Two- and 1.5-Stage.
- Dec 01, 2025
- The Journal of arthroplasty
- James Cashman + 14 more +14
Publications from 2021 to 2026
Showing 10 of 137 papers
2025 ICM: Abbreviated Two- and 1.5-Stage.
Artificial Intelligence Across the Prostate Cancer Pathway: Screening, Imaging, Pathology, and Biomarkers
Artificial intelligence (AI) has made great changes to prostate cancer screening and early detection across biomarkers, imaging, and pathology. On micro-ultrasound (micro-US), AI improves discrimination and raises specificity at comparable sensitivity versus clinical models, while multimodal magnetic resonance imaging-transrectal US (MRI-TRUS) AI achieves higher specificity at matched sensitivity. Liquid-biopsy programs combine fragmentomics with ctDNA and cell-free mRNA interpreted by AI, enabling noninvasive risk stratification and clinical feasibility. In imaging, AI for MRI matches or exceeds expert radiologists in large reader studies and MRI benchmarks; commercial tools show robust patient- and lesion-level performance. Quantitative pipelines (e.g., automated tissue-composition metrics) aid equivocal Prostate Imaging-Reporting and Data System (PI-RADS 3) lesions with PSA density, and AI-derived intraprostatic tumor volume offers independent prognostic value. Multimodal fusion of MRI with TRUS boosts detection, and automated prostate-specific membrane antigen (PSMA) PET/CT algorithms quantify tumor burden and support longitudinal response tracking. In pathology, clinical-grade AI automates cancer detection and Gleason grading, cutting reading time, ancillary tests, and second-opinion requests, while supporting integrative prognostic models. Downstream, AI accelerates radiotherapy planning, guides focal therapies and surgical margins, personalizes systemic therapy, and enables early post-treatment monitoring. Translation still requires rigorous, prospective, multi-site validation.
Read moreNear-Infrared Fluorescence Imaging in General Surgery: Applications in Vascularization, Tumor Margin Detection, and Biliary Anatomy
Near-infrared fluorescence (NIRF) imaging has emerged as a transformative intraoperative tool in general surgery, helping in vascular surgery interventions, tumor margin detection in different specialties, and biliary anatomy with high sensitivity and safety. Indocyanine green remains the gold-standard fluorescent agent, widely applied in angiography, tumor margin detection, and fluorescence cholangiography, consistently improving surgical safety and efficiency with exceedingly low complication rates. Recent advances and trends include activatable and targeted probes, near-infrared II fluorophores, and nanoparticle-based agents, which expand specificity, depth of imaging, and multiplexing capacity. Integration with robotic systems in general surgery practice and artificial intelligence may further strengthen the precision of fluorescence-guided surgery, providing automated interpretation and workflow integration. Clinical outcomes demonstrate reduced operative times, improved anatomical visualization during operations, and enhanced tumor resection accuracy, while emerging technologies promise broader applications in complex oncologic and hepatopancreatobiliary surgery. Taken together, NIRF imaging represents a rapidly evolving field with the potential to redefine intraoperative guidance and precision in general surgery.
Read moreReimagining Heart Failure Care: Highlights from ACC 2025.
Biodegradable-polymer versus durable-polymer drug-eluting stents in left main percutaneous coronary intervention: final results of the randomised IDEAL-LM trial.
Item does not contain fulltext
Bilateral synchronous multiple lung cancer: an emerging problem.
Multiple primary lung cancersare becoming increasingly recognised and pose diagnostic and staging uncertainties with challenging management options and prognostication. We describe a case of synchronous multiple primary lung canceroccurring bilaterally, and the steps in reaching the diagnosis, initial surgical management, the intensive follow-up this underwent, and how its subsequent recurrence led to treatment with radiation therapy in light of the patient's declining fitness. This case highlighted that cytological recurrence could occur prior to radiological recurrence, especially for endobronchial tumors, and intensive follow-up both radiologically and endoscopically with multidisciplinary input is crucial in the management of these challenging cases where evidence-based guidelines are limited.
Read more970 A Parisian Pain in the Groin; a Case of De Garengeot’s Hernia
Abstract Introduction 77-year-old gentleman presented with a four-day history of a painful right sided irreducible groin swelling. Background of previous bilateral mesh inguinal hernia repair thirty years prior. Differential diagnosis- recurrent incarcerated inguinal hernia. Description Emergency presentation with a painful right sided groin lump with history of previous inguinal hernia repair. Past medical history of AF on rivaroxaban, HTN and BPH. Patient systemically well with an irreducible lump in the right groin. CTAP showed recurrence of hernia in right inguinal region containing fat stranding and a 2cm-sized fluid-filled structure (suspected appendix). Taken to theatre the following day - oblique incision in right groin. Obvious femoral hernia identified. Haemorrhagic fluid and a necrotic appendix contained in hernia sac. Open appendicectomy performed through groin incision and femoral canal plicated using 2.0 prolene. No mesh used due to risk of contamination. Discharged day 2 post-op. Pathology confirmed acute appendicitis. Discussion Extremely rare case presentation. Femoral hernias account for 3% of all hernias and De Garengeot hernias only 1% of all femoral hernias. Furthermore, De Garengeot hernia with acute appendicitis accounts for only 0.01% of femoral hernias and are much more common in females than males with a 4:1 ratio. Femoral hernias are fifteen times more common in patients who have undergone previous inguinal hernia repair with 33% of men and 4% of women with De Garengeot hernia having undergone previous right inguinal hernia repair. Difficult pre-operative diagnosis given rarity with only 30% of cases diagnosed on pre-operative imaging-initial diagnosis Amyand hernia on CT imaging.
Read moreSymptomatic Heart Failure With Preserved Ejection Fraction: Is It Too Late to Consider Additional Therapies?
Diagnoses and treatments for participants with interstitial lung abnormalities detected in the Yorkshire Lung Screening Trial
IntroductionInterstitial lung abnormalities (ILA) are relatively common incidental findings in participants undergoing low-dose CT screening for lung cancer. Some ILA are transient and inconsequential, but others represent interstitial lung disease (ILD). Lung cancer screening therefore offers the opportunity of earlier diagnosis and treatment of ILD for some screening participants.MethodsThe prevalence of ILA in participants in the baseline screening round of the Yorkshire Lung Screening Trial is reported, along with the proportion referred to a regional ILD service, eventual diagnoses, outcomes and treatments.ResultsOf 6650 participants undergoing screening, ILA were reported in 169 (2.5%) participants. Following review in a screening review meeting, 56 participants were referred to the ILD service for further evaluation (0.8% of all screening participants). 2 participants declined referral, 1 is currently awaiting review and the remaining 53 were confirmed as having ILD. Eventual diagnoses were idiopathic pulmonary fibrosis (n=14), respiratory bronchiolitis ILD (n=4), chronic hypersensitivity pneumonitis (n=2), connective tissue disease/rheumatoid arthritis-related ILD (n=4), asbestosis (n=1), idiopathic non-specific interstitial pneumonia (n=1), sarcoidosis (n=1) and pleuroparenchymal fibroelastosis (n=1). Twenty five patients had unclassifiable idiopathic interstitial pneumonia. Overall, 10 people received pharmacotherapy (7 antifibrotics and 3 prednisolone) representing 18% of those referred to the ILD service and 0.15% of those undergoing screening. 32 people remain under surveillance in the ILD service, some of whom may require treatment in future.DiscussionLung cancer screening detects clinically significant cases of ILD allowing early commencement of disease-modifying treatment in a proportion of participants. This is the largest screening cohort to report eventual diagnoses and treatments and provides an estimate of the level of clinical activity to be expected by ILD services as lung cancer screening is implemented. Further research is needed to clarify the optimal management of screen-detected ILD.Trial registration numberISRCTN42704678.
Read moreSerum Irisin Levels Are Inversely Correlated With the Severity of Coronary Artery Disease Confirmed by Coronary Angiography: A Comparative Cross-Sectional Study.
Introduction Irisin, a newly discovered myokine, has been reported for its role in coronary artery disease (CAD), which is a major cause of mortality worldwide. Atherosclerosis is the primary cause of CAD. Irisin has been reported to reduce atherosclerosis by improving endothelial function and inhibiting inflammation via iNOS/NF-κB pathways. We sought to investigate the relationship between serum irisin levels and the severity of CAD that is confirmed with coronary angiography. Methods A comparative cross-sectional study was designed between the Chemical Pathology and Cardiology departments at KEMU/Mayo Hospital in Lahore, Pakistan. Patients were divided into group A with mild CAD (<50% stenosis) and group B with moderate-severe CAD (>50% stenosis). Serum was collected from venous blood, and irisin levels were analyzed by ELISA. Inclusion criteria: patients with stable CAD. Exclusion criteria: History of coronary artery bypass grafting (CABG), acute coronary syndrome (ACS), active or chronic infection, hepatic or renal dysfunction. Results The mean + SD age (years) of patients in group B (57.0±9.5) was significantly higher than group A (50.0±13.7). Irisin levels (μg/ml) were significantly higher in group A (15.3±4.6) than in group B (9.3±2.4). Irisin levels were significantly negatively correlated with the severity of CAD (% stenosis). Conclusion Serum irisin levels are low in patients with moderate to severe CAD, and they are negatively correlated with the severity of CAD (% stenosis).
Read more